FIELD: medicine.
SUBSTANCE: invention relates to a composition for the treatment and/or prevention of cardiovascular diseases, such as hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease, vascular disease, stroke, atherosclerosis, arrhythmia, hypertension, myocardial infarction. The composition contains less than 30% by weight of ethyl composite ester of docosahexaenoic acid (DHA) of the total weight of the composition, at least 60% of ethyl composite ester of eicosapentaeonic acid (EPA) by weight of all fatty acids, and composite ester of polyoxyethylene and sorbitan, and poloxamer in the amount from 0.25% to 15% relatively to the total weight of the composition.
EFFECT: invention provides for the stability of a composition in conditions of illumination, heating, moisture content, acid/basic hydrolysis, and/or in oxidizing conditions without the destruction of active ingredients.
19 cl, 4 dwg, 1 ex
